Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.47 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598772 | 0.99 | ERAP2 (0.48) | ERAP2ERAP1LNPEPSLC15A2OPRK1 | |
| SCHEMBL5598767 | 0.99 | ERAP2 (0.48) | ERAP2ERAP1LNPEPSLC15A2OPRK1 | |
| SCHEMBL4587311 | 0.98 | ERAP2 (0.47) | ERAP2ERAP1LNPEPSLC15A2OPRK1 | |
| SCHEMBL29937046 | 0.97 | ERAP2 (0.47) | ERAP2ERAP1LNPEPSLC15A2OPRK1 | |
| SCHEMBL29937022 | 0.97 | ERAP2 (0.47) | ERAP2ERAP1LNPEPSLC15A2OPRK1 | |
| SCHEMBL29937026 | 0.96 | ERAP2 (0.46) | ERAP2ERAP1LNPEPSLC15A2OPRK1 | |
| SCHEMBL30906004 | 0.95 | ERAP2 (0.44) | ERAP2ERAP1LNPEPSLC15A2OPRK1 | |
| SCHEMBL5792593 | 0.92 | SLC15A2 (0.51) | ERAP2ERAP1LNPEPSLC15A2OPRK1 | |
| SCHEMBL31472846 | 0.92 | ERAP2 (0.43) | ERAP2ERAP1LNPEPSLC15A2OPRK1 | |
| SCHEMBL31472847 | 0.92 | ERAP2 (0.43) | ERAP2ERAP1LNPEPSLC15A2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | PROCYTE CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7179789-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PROCYTE CORPORATION (US) | 2005-09-08 | — | — | US | disclosed |
| US-6927205-B2 | Compositions and methods for treatment of psoriasis | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| US-6927206-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | CUTA, AOC1, RCN1 | ERAP2 279/4885ERAP1 209/4885LNPEP 352/4885 |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | ERAP2 633/4885ERAP1 366/4885LNPEP 19/4885 |
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | CUTA, TYR, EYA3 | ERAP2 218/4885ERAP1 497/4885LNPEP 78/4885 |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PTH1R, TSLP, CYP27B1 | ERAP2 1717/4885ERAP1 1652/4885LNPEP 1138/4885 |
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, CTRC | ERAP2 698/4885ERAP1 423/4885LNPEP 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.